<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288208</url>
  </required_header>
  <id_info>
    <org_study_id>TL32711-POC-0095-PTL</org_study_id>
    <nct_id>NCT02288208</nct_id>
  </id_info>
  <brief_title>Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B</brief_title>
  <official_title>Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TetraLogic Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TetraLogic Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of birinapant in subjects with chronic Hepatitis B who are
      currently receiving anti-viral therapy with either tenofovir or entecavir. Patients will
      receive either birinapant or placebo in addition to their anti-viral therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to cranial nerve palsies observed
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From Screening through end of study, up to 13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of birinapant (in plasma): maximum concentration (Cmax), time of maximum concentration (Tmax), area under the curve (AUC) extrapolated to time infinity, AUC from dosing to last quantifiable concentration</measure>
    <time_frame>Day -1 through Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of birinapant (in plasma): terminal elimination half-life (t1/2), clearance (CL), terminal disposition rate constant,volume of distribution (Vdss)</measure>
    <time_frame>Day -1 through Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of oral antiviral medication (tenofovir or entecavir): Cmax, Tmax, AUC from dosing to last quantifiable concentration, t1/2, CL, terminal disposition rate constant, Vdss</measure>
    <time_frame>Day -1, Day 1 and Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B markers (Determine levels of HBsAg, HBeAg, HBV DNA, and HBsAb)</measure>
    <time_frame>Screening through Day 29</time_frame>
    <description>Determine levels of HBsAg, HBeAg, HBV DNA, and HBsAb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effect of birinapant on cIAP1 and cIAP2 levels in peripheral blood mononuclear cells (PBMC) and levels of cluster of differentiation 4 and 8 (CD4+, CD+8) lymphocytes</measure>
    <time_frame>Screening through Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Antiviral Therapy &amp; Birinapant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and birinapant administered as a 30 minute IV infusion once weekly for four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiviral Therapy &amp; Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and placebo (for birinapant) administered as a 30 minute infusion once weekly for four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiviral Therapy (tenofovir or entecavir)</intervention_name>
    <arm_group_label>Antiviral Therapy &amp; Birinapant</arm_group_label>
    <arm_group_label>Antiviral Therapy &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Birinapant</intervention_name>
    <arm_group_label>Antiviral Therapy &amp; Birinapant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for birinapant)</intervention_name>
    <arm_group_label>Antiviral Therapy &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented history of chronic Hepatitis B infection currently being treated with
             tenofovir or entecavir for at least 3 months

          -  Measurable titer of HBsAg

          -  HBV DNA level &lt; 2 log copies/mL or 10² copies/mL

          -  No more than Child-Pugh score of 5 plus a valid FibroScan® of at least 10 readings
             with a median score of &lt;7 and interquartile range of &lt; 30%

          -  Adequate liver function, aspartate AST and ALT ≤2 x ULN

          -  Adequate renal function as evidenced by creatinine ≤2 mg/dL

        Exclusion Criteria:

          -  Participation in any interventional study within 4 weeks prior to Screening

          -  Known HIV infection, Hepatitis C, or other significant hepatic disorder including
             cirrhosis (Child-Pugh Class B or C)

          -  Serious illness or autoimmune disease or other known liver disease

          -  Uncontrolled hypertension

          -  Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or
             clinically significant cardiac disease

          -  Currently breast feeding, pregnant or planning on becoming pregnant

          -  Known allergy or hypersensitivity to any of the formulation components of birinapant
             or placebo, including citric acid

          -  History of cranial nerve palsy

          -  Current treatment with anti-TNF therapies or has received treatment with anti-TNF
             therapies within the last 6 months

          -  Use of non-steroidal anti-inflammatory drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CMAX / Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleus Network Limited / AMREP Precinct</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

